Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

1.

Development of a recombinant antibody towards PAPP-A for immunohistochemical use in multiple animal species.

Mikkelsen JH, Steffensen LB, Oxvig C.

J Immunol Methods. 2014 Feb;404:33-40. doi: 10.1016/j.jim.2013.12.002. Epub 2013 Dec 12.

PMID:
24333852
2.

Thrombolysis in anterior spinal artery syndrome.

Müller KI, Steffensen LH, Johnsen SH.

BMJ Case Rep. 2012 Sep 7;2012. pii: bcr2012006862. doi: 10.1136/bcr-2012-006862.

PMID:
22962400
3.

What is needed to keep persons with multiple sclerosis vitamin D-sufficient throughout the year?

Steffensen LH, Brustad M, Kampman MT.

J Neurol. 2013 Jan;260(1):182-8. doi: 10.1007/s00415-012-6611-6. Epub 2012 Aug 1.

PMID:
22850935
4.

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

IST-3 collaborative group, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A.

Lancet. 2012 Jun 23;379(9834):2352-63. doi: 10.1016/S0140-6736(12)60768-5. Epub 2012 May 23. Erratum in: Lancet. 2012 Aug 25;380(9843):730.

5.

Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial.

Kampman MT, Steffensen LH, Mellgren SI, Jørgensen L.

Mult Scler. 2012 Aug;18(8):1144-51. doi: 10.1177/1352458511434607. Epub 2012 Feb 21.

PMID:
22354743
6.

Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited.

Sandercock P, Lindley R, Wardlaw J, Dennis M, Innes K, Cohen G, Whiteley W, Perry D, Soosay V, Buchanan D, Venables G, Czlonkowska A, Kobayashi A, Berge E, Slot KB, Murray V, Peeters A, Hankey GJ, Matz K, Brainin M, Ricci S, Cantisani TA, Gubitz G, Phillips SJ, Antonio A, Correia M, Lyrer P, Kane I, Lundstrom E; IST-3 collaborative group.

Trials. 2011 Nov 30;12:252. doi: 10.1186/1745-6215-12-252.

7.

Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial.

Steffensen LH, Jørgensen L, Straume B, Mellgren SI, Kampman MT.

J Neurol. 2011 Sep;258(9):1624-31. doi: 10.1007/s00415-011-5980-6. Epub 2011 Mar 13.

8.

The role of vitamin D in multiple sclerosis.

Kampman MT, Steffensen LH.

J Photochem Photobiol B. 2010 Nov 3;101(2):137-41. doi: 10.1016/j.jphotobiol.2010.04.003. Epub 2010 Apr 21. Review.

PMID:
20471852
9.

Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis.

Steffensen LH, Mellgren SI, Kampman MT.

J Neurol. 2010 Mar;257(3):410-8. doi: 10.1007/s00415-009-5337-6. Epub 2009 Oct 1. Erratum in: J Neurol. 2010 Mar;257(3):497-8.

PMID:
19795152
10.

Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.

Kampman MT, Steffensen LH.

Ir J Med Sci. 2009 Jun;178(2):235-6; author reply 237-8. doi: 10.1007/s11845-009-0275-y. Epub 2009 Jan 31. No abstract available.

PMID:
19184608
12.

Responses at the translational level to heterologous expression of the Na,K-ATPase.

Steffensen L, Pedersen PA.

Ann N Y Acad Sci. 2003 Apr;986:539-40. No abstract available.

PMID:
12763882
13.

[Use of statins in hospitals after myocardial infarction].

Notø AT, Steffensen L, Nordøy A, Hansen JB.

Tidsskr Nor Laegeforen. 2001 Sep 10;121(21):2467-71. Norwegian.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk